Statistics from Altmetric.com
While the majority of patients with psoriatic arthritis (PsA) respond well to treatment with adalimumab, some patients lose response.1 An explanation might be the development of antiadalimumab antibodies, which has been reported in rheumatoid arthritis.2 3 Therefore, we studied the incidence of antiadalimumab antibodies in PsA, and the relationship with serum adalimumab concentration and clinical response.
Twenty-two patients with active PsA, fulfilling CASPAR classification criteria,4 started adalimumab treatment (table 1). The patients met the requirements of the Dutch consensus on initiation of tumour necrosis factor blocking therapy in PsA5 and were seen at baseline, and after 3 and 12 months. Serum samples were collected just before the next injection with adalimumab. The Disease Activity Score in 28 joints (DAS28), which has been shown to discriminate between active drug and placebo in clinical trials in …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.